Master Alliance Provisions Guide (MAPGuide)

Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement

  • Term & termination | Effects of termination

<p><span style=”textdecoration: underline;”><strong>13. Term and Terminationstrong>span>p>
<p><b>13.3 Effects of Expiry and Terminationb>p>
<p>13.3.1 <span style=”fontweight: 400;”>Where Gavi terminates this Agreement pursuant to <span style=”textdecoration: underline;”><a href=”” target=”_blankrel=”noopener“>Clause 13.2a>span>, Novavax shall promptly refund Gavi any portion of the <span style=”textdecoration: underline;”><a href=”” target=”_blankrel=”noopener“>Advance Payment Amounta>span> which has not already been credited against the Purchase Price for a Binding Purchase Order placed by a COVAX Buyer.span>p>
<p>13.3.2 <span style=”fontweight: 400;”>Expiry or Termination of this Agreement shall not release either Party from any commitment under this Agreement or any liability that, at the Termination Effective Date, has already accrued to the other Party, or release Novavax from any obligations under a Supply Agreement.span>p>
<p>13.3.3 <span style=”fontweight: 400;”>Subject to Clause 13.3.2, the Parties acknowledge and agree that the Partiesrights and obligations under this Agreement shall terminate conclusively from and after the Termination Effective Date. For clarity, in the event of a Termination by Gavi under Clause 13.2.1 or Clause 13.2.2 of this Agreement, Gavi shall not be obliged to make any Balancing Payments for Remaining Doses.span>p>
<p>13.3.4 <span style=”fontweight: 400;”>A Party shall not be entitled to any compensation for any loss, damage, liability or expense incurred as a result of the proper exercise by the other Party of any right to terminate this Agreement.span>p>
<p><b>13.4 Survival of Clauses.b><span style=”fontweight: 400;”>Any other term of this Agreement by its nature intended to survive Termination of this Agreement survives Termination of this Agreement, including this Clause 13.4 (span><i><span style=”fontweight: 400;”>Survival of Clausesspan>i><span style=”fontweight: 400;”>) and Clauses 3 (span><i><span style=”fontweight: 400;”>Vaccine Variationspan>i><span style=”fontweight: 400;”>), 4.4 (span><i><span style=”fontweight: 400;”>Novavax Supplyspan>i><span style=”fontweight: 400;”>), 7.2 (span><i><span style=”fontweight: 400;”>Delivery, Variance, Short Supplyspan>i><span style=”fontweight: 400;”>), 8.2(span><i><span style=”fontweight: 400;”>Fulfilment of Gavi Obligationsspan>i><span style=”fontweight: 400;”>), 9 (span><i><span style=”fontweight: 400;”>Provision of Informationspan>i><span style=”fontweight: 400;”>), 10 (span><i><span style=”fontweight: 400;”>Auditspan>i><span style=”fontweight: 400;”>), 12 (span><i><span style=”fontweight: 400;”>Liability, Insurance, Indemnificationspan>i><span style=”fontweight: 400;”>), 13.3 (span><i><span style=”fontweight: 400;”>Effects of Expiry and Terminationspan>i><span style=”fontweight: 400;”>), 13.5 (span><i><span style=”fontweight: 400;”>Public Health Licensespan>i><span style=”fontweight: 400;”>), 14(span><i><span style=”fontweight: 400;”>Disputes, Arbitration, Expert Determinationspan>i><span style=”fontweight: 400;”>), and 16 (span><i><span style=”fontweight: 400;”>Generalspan>i><span style=”fontweight: 400;”>).span>p>